TABLE 1.
Selecteda baseline characteristics
| Before matching | After matching | |||||
|---|---|---|---|---|---|---|
| Controls | Recipients | Controls | Recipients | |||
| (N = 232,521) | (N = 2,083) | SMD | (N = 7,014) | (N = 1,878) | SMD | |
| Age on 31 Dec 2021 | ||||||
| Mean (SD) | 65 (14.1) | 68 (10.5) | 28.1 | 69 (10.5) | 69 (10.3) | −2.5 |
| Sex | ||||||
| Male | 203,678 (88%) | 1,909 (92%) | 13.3 | 6,620 (94%) | 1,753 (93%) | −4.3 |
| Race/ethnicity | ||||||
| Black: non-Hispanic Black | 48,372 (21%) | 310 (15%) | −15.5 | 996 (14%) | 273 (15%) | 1 |
| Hispanic any race | 15,044 (6%) | 89 (4%) | −9.8 | 179 (3%) | 59 (3%) | 3.5 |
| Other | 16,517 (7%) | 148 (7%) | 0 | 399 (6%) | 119 (6%) | 2.7 |
| White: non-Hispanic White | 152,588 (66%) | 1,536 (74%) | 17.7 | 5,440 (78%) | 1,427 (76%) | −3.7 |
| Number of vaccinations | ||||||
| Zero-dose vaccine | 53,195 (23%) | 87 (4%) | −56.8 | 260 (4%) | 71 (4%) | 0.4 |
| Two-dose vaccineb | 179,326 (77%) | 1,996 (96%) | 56.8 | 6,754 (96%) | 1,807 (96%) | −0.4 |
| Third dose of vaccine | 96,330 (41%) | 1,650 (79%) | 83.7 | 3,989 (57%) | 1,501 (80%) | 51.2 |
| BMI category | ||||||
| Missing | 11,262 (5%) | 54 (3%) | −11.9 | 110 (2%) | 35 (2%) | 2.3 |
| Normal | 59,953 (26%) | 603 (29%) | 7.1 | 1,935 (28%) | 529 (28%) | 1.3 |
| Overweight/obese | 161,306 (69%) | 1,426 (68%) | −2 | 4,969 (71%) | 1,314 (70%) | −1.9 |
| DCCI | ||||||
| Mean (SD) | 1.7 (2.09) | 2.8 (2.326) | 53.1 | 2.2 (2.26) | 2.7 (2.16) | 24.1 |
| Immunocompromised status | ||||||
| Diagnoses of immunocompromising condition or use of immunosuppressants | 232,521 (100%) | 2,083 (100%) | 0 | 7,014 (100%) | 1,878 (100%) | 0 |
| Specific immunocompromising conditions | ||||||
| Cancerc | 32,708 (14%) | 804 (39%) | 58 | 1,187 (17%) | 745 (40%) | 52.2 |
| Cancer, metastaticc | 7,281 (3%) | 56 (3%) | −2.6 | 268 (4%) | 53 (3%) | −5.6 |
| HIVc | 1,178 (1%) | 32 (2%) | 10.3 | S | S | S |
| Hematologic cancerc | 9,177 (4%) | 702 (34%) | 82.3 | 361 (5%) | 657 (35%) | 80.3 |
| Rheumatoid arthritisc | 18,412 (8%) | 269 (13%) | 16.4 | 668 (10%) | 208 (11%) | 5.1 |
| Solid organ transplantc | 9,014 (4%) | 437 (21%) | 53.7 | 575 (8%) | 400 (21%) | 37.6 |
| Any immunocompromisingcondition | 85,268 (37%) | 1,619 (78%) | 91.2 | 3,302 (47%) | 1,449 (77%) | 65.2 |
| Other underlying conditions | ||||||
| Coronary artery disease | 33,459 (14%) | 357 (17%) | 7.5 | 1,329 (19%) | 322 (17%) | −4.7 |
| Chronic kidney disease | 24,759 (11%) | 512 (25%) | 37.2 | 1,528 (22%) | 432 (23%) | 2.9 |
| Chronic obstructive pulmonary disease | 44,534 (19%) | 398 (19%) | −0.1 | 1,088 (16%) | 322 (17%) | 4.4 |
| Diabetes mellitus w/complications | 25,257 (11%) | 340 (16%) | 16 | 1,132 (16%) | 305 (16%) | 0.3 |
| Diabetes mellitus w/ocomplications | 38,284 (16%) | 353 (17%) | 1.3 | 1,299 (19%) | 326 (17%) | −3 |
| Hypertension | 125,278 (54%) | 1,308 (63%) | 18.2 | 4,468 (64%) | 1,174 (63%) | −2.5 |
a
See Table S2 for complete definitions of variables and Table S3 for distribution of all the baseline characteristics.
b
Includes one dose of Janssen.
c
These conditions are included in the definition of immunocompromising conditions.